Bayer's Sunharbo Rollout Gives Its Pharma Turnaround a Deadline

Bayer has set a concrete date for the commercial phase of its most closely watched new medicine. Shipments of Sunharbo are slated to begin in the United States between mid- and late November, the company said, turning an approved drug into a marketed product and shifting investor attention from laboratory risk to sales execution.

That transition has a clear yardstick. The FDA cleared Asundexian under the Sunharbo brand, and by Bayer's account it is the world's first approved factor XIa inhibitor. It is indicated to lower the risk of a repeat stroke in certain adults, used alongside antiplatelet therapy following a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The label's boundaries matter for anyone modelling the drug's value: the commercial case has to be built on the approved indication, not a broader one.

The clinical numbers behind the approval are respectable rather than spectacular. The FDA puts the reduction in ischemic stroke risk versus placebo at 26%, with a median treatment duration of 14.2 months in the pivotal study. What makes the news notable is the pairing of that benefit with a firm delivery timetable — Bayer can now point to a specific product at a specific moment.

Two brokers, two different yardsticks

Yesterday's analyst notes captured how far apart the readings can be. Jefferies kept Bayer at "Hold" with a price target of 48.50 euros; analyst Michael Leuchten called the approval expected and said the risk attached to Bayer's pharmaceutical pipeline had fallen substantially. That distinction is the one that matters for valuation — a lower development risk strengthens the investment case only to the extent the share price has not already priced the progress in.

Should investors sell immediately? Or is it worth buying Bayer?

Deutsche Bank took the more constructive route, lifting its target to 65 euros from 60 and reaffirming its buy recommendation. More telling than the headline target was the earnings revision beneath it: the broker raised its forecast for adjusted EBITDA in the 2026 financial year by roughly 3% to 10,060 million euros. Analyst Virginie Boucher-Ferte also nudged her EBITDA and earnings-per-share estimates for 2027 and 2028 up by about 3% each, extending the sunnier view well beyond the current year.

The revision is not uniform. Pharma is doing the heavy lifting, while expectations for Crop Science were trimmed slightly. That split is the heart of the thesis: Bayer has to deliver where analysts now expect more, and the agricultural unit's softness has to be absorbed.

The operating evidence is already visible

Third-quarter 2026 figures give the optimism some substance. Pharma EBITDA climbed 23.6%, with the margin reaching 27.6%. Among the growth engines, Nubeqa lifted revenue by 58.3% in currency-adjusted terms to roughly one billion euros, while Kerendia posted a 64.9% sales increase. The durability of those two products may matter as much as the hopes pinned on newer pipeline assets — they are the concrete test of whether Bayer can meet its raised profit assumptions.

Bayer had already improved its full-year outlook about a week before the Deutsche Bank note, so the broker's move extends an existing trend rather than starting one.

Cash remains the weak link

The financial cross-check is less flattering. Bayer booked a net loss of 672 million euros in the third quarter of 2026 and a free cash flow of minus 293 million euros. Net financial debt stood at 31.1 billion euros at the end of September 2026, a figure that already reflects three billion euros in proceeds from the Apollo transaction.

Bayer at a turning point? This analysis reveals what investors need to know now.

Debt reduction is progress, but it counts for more if the underlying business contributes to it. Higher adjusted earnings only strengthen the case when they translate into real financial headroom — a better cash inflow would give the operating gains weight and underpin further deleveraging. Weaker agriculture and the negative free cash flow continue to weigh on the overall picture, which is why the improved earnings outlook and the balance-sheet strain are best read side by side.

The upshot is a more credible story with a nearer-term test. Sunharbo's November rollout marks the point where a clinical result and a regulatory green light must become a business contribution, while the cash flow statement will decide whether Deutsche Bank's brighter numbers turn into lasting financial strength.

Ad

Bayer Stock: New Analysis - 11 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...